Human evolution: the non-coding revolution. by Franchini, Lucía F & Pollard, Katherine S
UCSF
UC San Francisco Previously Published Works
Title
Human evolution: the non-coding revolution.
Permalink
https://escholarship.org/uc/item/4ff2w83v
Journal
BMC biology, 15(1)
ISSN
1741-7007
Authors
Franchini, Lucía F
Pollard, Katherine S
Publication Date
2017-10-02
DOI
10.1186/s12915-017-0428-9
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Franchini and Pollard BMC Biology  (2017) 15:89 
DOI 10.1186/s12915-017-0428-9REVIEW Open AccessHuman evolution: the non-coding
revolution
Lucía F. Franchini1 and Katherine S. Pollard2,3*Abstract
What made us human? Gene expression changes
clearly played a significant part in human evolution, but
pinpointing the causal regulatory mutations is hard.
Comparative genomics enabled the identification of
human accelerated regions (HARs) and other human-
specific genome sequences. The major challenge in the
past decade has been to link diverged sequences to
uniquely human biology. This review discusses
approaches to this problem, progress made at the
molecular level, and prospects for moving towards
genetic causes for uniquely human biology.our biology. Second, we know much less about how se-Post-genomic challenges for determining
uniquely human biology
When the human genome was first sequenced [1, 2], the
big question was “how many genes do we have?” Most
people guessed too high. Sequencing our closest living
relative, the chimpanzee [3, 4], begged the question
“which genes are different?” Here the answer was pre-
dicted a century before and supported by King and Wil-
son’s 1975 discovery that certain blood proteins have
very few amino acid differences between human and
chimpanzee [5, 6]. We now know that the vast majority
of all genomic changes that happened since the human–
chimpanzee ancestor are in non-coding regions, consist-
ent with King and Wilson’s hypothesis that regulatory
changes drove the differences between our species. In
hindsight, the importance of gene regulation in human
evolution is logical. There are many more DNA bases in
regulatory regions than in protein-coding genes, making
them a larger target for evolutionary innovation. Fur-
thermore, genes frequently function in many different* Correspondence: kpollard@gladstone.ucsf.edu
2Gladstone Institutes, San Francisco, CA 94158, USA
3Department of Epidemiology & Biostatistics, Institute for Human Genetics,
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(http://creativecommons.org/publicdomain/zecontexts, and this pleiotropy constrains their evolution
compared to regulatory elements, which tend to be more
modular [7]. Thus, regulatory sequences have great po-
tential to be drivers of human evolution.
The challenge in the post-genomic era has been to de-
termine which of the millions of human-specific non-
coding sequence differences are responsible for the
unique aspects of our biology. This is a hard problem
for many reasons. First, the non-coding genome is vast,
requiring methods to prioritize the mutations that mat-
ter. The neutral theory of molecular evolution, coupled
with redundancy in biological networks, suggests that
many human-specific DNA changes had little effect on
quence determines function of regulatory elements com-
pared to protein or RNA genes. Hence it is difficult to
predict the molecular, cellular, and organismal conse-
quences of human-specific regulatory mutations. Fur-
thermore, most uniquely human traits are complex, and
there is no doubt that they are encoded by a combin-
ation of mutations in different genomic loci. Finally, be-
cause gene regulation has diverged significantly between
primates and model organisms such as mice, zebrafish
or flies, it is hard to test hypotheses about the functional
effects of regulatory mutations. In this review, we discuss
advances to address these barriers with an emphasis on
linking sequence to function, complementing other re-
cent papers that explore genetic and regulatory changes
in human evolution [8–13].Discovering the fastest evolving regions in the
human genome
Single nucleotide changes can have functional conse-
quences, but currently these are difficult to predict in
non-coding regions where small mutations are frequently
tolerated and the function of a particular nucleotide is
rarely known. Hence, human evolutionary genetics has
mostly focused on genome regions with many human-
specific differences (reviewed in [14–17]). Human acceler-
ated regions (HARs) are short, evolutionarily conservedis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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DNA substitutions than expected in the human lineage
since divergence from chimpanzees. A number of studies
applied different tests to identify HARs either genome-
wide [18, 19] or with protein-coding sequences specifically
removed from the analysis [20–23]. We and the other au-
thors of these studies had a common aim: to identify regu-
latory elements with human-specific activity (Fig. 1).
These analyses started with regions conserved across non-
human mammals in order to enrich for functional
elements [24–27] and to increase power to detect acceler-
ation (Box 1). Then they used various methods to identify
a subset of conserved elements that accumulated human-
specific changes. Differences in analysis choices and avail-
able data over time (for example, species in alignments,
methods used to identify conserved elements, tests for ac-
celeration, bioinformatics filters to remove artifacts) re-
sulted in only modest overlap between the HARs
identified in different studies despite their common aim
(Fig. 1). These studies also differed in whether they specif-
ically tested for positive selection compared to a neutral
model or simply identified acceleration, which could be
due to a variety of evolutionary processes including
mutation rate increases or loss of constraint (Box 1).Fig. 1. Identification of human accelerated elements. Top: the four differen
differences include (i) the conserved elements used as candidates to identi
detect conservation, and whether human was masked in the alignments),
and/or remove assembly or alignment artifacts, and (iii) tests used to detec
celerated regions. Abbreviations: ANC accelerated conserved non-coding se
quences [23]; HTBE human terminal branch elements [21]. HARs include theCollectively nearly 3000 non-coding HARs have been
identified to date [14], representing a pool of candidates
that can be searched for regulatory regions with human-
specific activity.
Insertions, deletions, duplications, and rearrangements—-
collectively known as structural variants (SVs)—contribute
many more nucleotides to the genetic difference between
humans and chimpanzees than do HARs and other single
nucleotide variants. Indeed, the first differences detected
between the human and chimp genomes were large SVs
discovered prior to genome sequencing (for example,
chromosome 2 fusion, inversions on chromosomes 1 and
18 [28]). Primates have accumulated SVs at an accelerated
rate compared to other mammals, and the human genome
contains numerous lineage-specific SVs [29, 30]. These SVs
contribute significantly to the emergence of new genes and
gene families (reviewed in [31]). Most HAR analyses have
specifically filtered out SVs due to the difficulty of accur-
ately assembling and aligning these regions. But HARs are
in fact common in recent segmental duplications [20], and
we found them to be enriched near duplicated genes [32].
In addition, SVs can change gene expression and pheno-
types by associating non-coding elements with genes they
did not previously regulate (‘enhancer hijacking’, see below)t approaches used to identify human accelerated regions. Some key
fy HARs (which depend on multiple sequence alignments, methods to
(ii) bioinformatics filters that aim to restrict to non-coding elements
t acceleration. Bottom: overlap of the different datasets of human ac-
quences [20]; HACNS human accelerated conserved non-coding se-
original HARs [19] and the second generation HARs or 2xHARs [100]
Box 1 Evolutionary forces underlying the appearance
of HARs
In order to detect acceleration in a particular lineage it is necessary
to statistically test for a difference between the substitution rate
observed on that lineage and the expected rate given the rest of
the tree. The tests to detect acceleration typically use continuous
time Markov models of DNA (or protein) evolution to quantify the
likelihood of the multiple sequence alignment for a genome region
[87]. Comparing human to chimpanzee and other primates,
acceleration tests can reach genome-wide significance even when
there are only a small number of human-specific substitutions in a ~
100-bp region. This is especially true in regions that are conserved
across non-human primates, because the number of expected sub-
stitutions is close to zero [14]
Is acceleration equal to positive selection? Not necessarily. In order to
differentiate positive selection from relaxation of constraint (both
mechanisms can produce acceleration) it is important to compare
the evolutionary rate of the accelerated element to the local neutral
rate. Using this approach, it has been shown that many HARs (~50%)
and haDHSs (~90%) are evolving faster than the neutral rate for that
part of the genome, which is suggestive of adaptive evolution [88].
These divergence-based tests will detect fixed differences that largely
accumulated millions of years ago. To test for recent or ongoing posi-
tive selection, one uses population genetics tests that detect reduced
polymorphism relative to divergence or long haplotypes. While many
sequence changes in HARs predate diversification of modern
humans, some HARs do show evidence for recent selection [19, 21,
88], as do some haDHSs [38]. Another mechanism that likely shaped
~ 20% of HARs is GC-biased gene conversion [88–90], a neutral
recombination-associated process that leads to accelerated fixation of
weak to strong (AT to GC) mutations. Another ~ 20% of HARs are not
evolving faster than neutral expectations, but only faster than ex-
pected given strong conservation in other species, perhaps due to
loss of functional constraint. Thus, there is not a unique underlying
evolutionary mechanism that led to the appearance of all HARs. The
interpretation of functional differences between orthologous se-
quences in HARs should consider different evolutionary forces.
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quences of human-specific SVs is clearly needed.
Beyond conservation: combining acceleration
tests and epigenetic marks
Sequence conservation is a useful tool for predicting
which non-coding substitutions will be functional. But
many regulatory elements are not conserved [35, 36],
and conservation does not indicate when and where aregulatory element is active. Since the initial discovery of
HARs and human-specific SVs, understanding of the
proteins and epigenetic marks found at particular cat-
egories of regulatory element has improved significantly,
as have genome-wide functional genomics assays such as
chromatin immunoprecipitation sequencing (ChIP-seq),
ATAC-seq, and RNA-seq. Using these tools it is now
possible to generate genome-wide maps of predicted
regulatory regions across many cell types and develop-
mental stages. We predicted enhancers in the human
genome and tested 29 predictions overlapping HARs
with in vivo reporter assays (see below), discovering that
many of the previously identified HARs are enhancers
active in the developing embryo [37].
Functional genomics data are also very useful for loos-
ening or omitting the requirement that HARs be con-
served in other species. Two recent investigations
performed evolutionary analyses of putative human
regulatory elements and identified many examples of hu-
man sequence acceleration missed by studies that relied
on deep sequence conservation (for example, greater
than 95% sequence identity across mammals or verte-
brate phastCons elements). Gittelman et al. performed
comprehensive evolutionary and population genetics
analyses on open chromatin (specifically, DNase I hyper-
sensitive sites (DHSs)) from 130 cell types to discover
regulatory DNA with evidence of adaptive evolution in
humans [38]. They discovered 524 DHSs with sequences
that are conserved in non-human primates but show ac-
celerated nucleotide substitution rates in the human
lineage (haDHS). By functionally characterizing selected
haDHSs using transgenic reporters and luciferase assays
in different cell types, the authors identified several
where the human sequence changes result in a gain of
enhancer function (Table 1; Fig. 2).
Using a similar approach, Dong et al. compared substi-
tution rates of DHSs to nearby ancestral repeats (LINE1
or LINE2 elements, assumed to be neutrally evolving)
and identified 3538 accelerated DHSs (ace-DHS) [39].
Notably, only 17 accelerated DHSs overlap between
these two studies, likely due to Gittelman et al. requiring
conservation in primates so that they tested only
113,577 DHSs versus 808,943 in Dong et al.’s analysis,
which had no such conservation filter. In addition, these
two approaches used different data to estimate neutral
rates for their acceleration tests. Regardless, it is clear
that starting with DHSs rather than conserved elements
reveals novel human-specific regulatory elements: the
majority of haDHSs (454/524) and ace-DHSs (3520/
3538) were not previously identified as HARs. It is
important, however, to validate the regulatory func-
tions of DHSs and other biochemically active genomic
regions experimentally, especially if they are not con-
served [36].
Box 2 Our place on earth: humans as primates
When Linnaeus (1758) described our species, he named us
Homo sapiens and placed us along with orangutans and
chimpanzees in the genus Homo like any other primate, even
though he believed that humans were special beings in God’s
creation. Since then diverse data (bones, embryology, fossils,
DNA) have verified our place on the tree of life, while also
revealing numerous differences between humans and other
primates, particularly our closest living relatives the
chimpanzees. These include distinct behaviors, morphological
characteristics, and molecular phenotypes [91, 92] (see also
http://carta.anthropogeny.org/content/about-moca). The
uniqueness of the human brain has been investigated in
particular detail. Although it is a very typical primate brain
overall [16, 93–95], the human brain seems to be unusual in
terms of the number of neurons [93, 96], spatial organization
[97], neuropil space, amount of dendritic branching, and
synaptic spine density [98, 99]
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An alternative approach to identify human-specific regula-
tory elements is to perform functional genomics assays
such as open chromatin or protein binding in multiple
species and find regions with differential evidence of regu-
latory activity. Some of the first evidence that human-
specific regulatory elements may be common came from
the ENCODE project, which found that a high proportion
(~50%) of the biochemically active regions identified in
the human genome were not conserved across mammals
[35, 40]. Several recent studies built on this observation
and compared human epigenomic profiles (such as open
chromatin, histone modifications) to those of primates
and other species using either primary tissues or cell lines
from various developmental stages (see below). To infer
that regulatory marks are human-specific requires epige-
nomic profiles from chimpanzees (or bonobos), which is
often impossible due to limited availability of material and
ethical considerations. One potential solution is to investi-
gate post hoc if the regions with epigenetic signatures that
differ between human and rodents or monkeys intersect
with HARs or harbor sequence changes that are unique to
the human genome.
Cotney and colleagues performed ChIP-seq for histone
H3 lysine 27 acetylation (H3K27ac, a mark of active en-
hancers) in human, rhesus macaque, and mouse embry-
onic limb at four different developmental stages from
bud to digit separation, defined as orthologous based on
morphology and HOXD gene expression [41]. They
found 2175 promoters and 2915 putative enhancers with
significantly higher H3K27ac signal in human at one ormore time points. Sixteen of these regions overlap with
HARs, but most show no evidence of human accelerated
substitution rates or unusual diversity patterns across
modern humans [41].
Using a similar approach, Reilly et al. mapped active
promoters and enhancers using di-methylation of his-
tone H2 lysine 27 (H3K27me2, a promoter mark) and
H3K27ac, respectively, during three stages of human,
rhesus macaque, and mouse cortex development [42].
Comparing signal for these epigenetic marks across spe-
cies, the authors predicted 2855 promoters and 8996 en-
hancers unique to human samples (that is, with higher
signal in human than other species). The majority of these
regions show no evidence of human accelerated substitu-
tion rates, although 48 of them overlap HARs [42].
Vermunt and colleagues assayed H3K27ac in eight ana-
tomical subdivisions of the adult brain (cerebellum, caud-
ate nucleus, thalamic nuclei, putamen, white matter,
precentral gyrus, prefrontal cortex, occipital pole) of hu-
man, chimpanzee and rhesus macaque [43]. The authors
found that 14–43% of putative enhancers and 3–10% of
promoters had differential signal between human and ma-
caque brain regions. However, only a very small fraction
of these showed a similar difference between human and
chimpanzee. While 284 H3K27ac regions from this study
overlap with HARs, only 32 of these have significantly
higher or lower H3K27ac signal in human versus chim-
panzee or macaque. One particularly interesting example
is 2xHAR87/HACNS548, which interacts with the pro-
moter of the CADM1 gene and shows steadily increasing
H3K27ac signal from macaque to human (Fig. 2).
Prescott et al. compared transcription factor (TF) and co-
activator binding, histone modifications, and chromatin ac-
cessibility genome-wide in human and chimpanzee cranial
neural crest cells (CNCCs) to pinpoint putative enhancers
[44]. They derived CNCCs from pluripotent stem cells
using an in vitro protocol in which specification, migration,
and maturation are recapitulated in the dish [45, 46], an ap-
proach that allows unavailable chimpanzee cell types to be
derived in the lab. The authors predicted ~ 1800 regulatory
elements with different levels of H3K27ac in human versus
chimpanzee, suggestive of differential enhancer activity. A
few of these overlap HARs (three of the top 1000; Table 1).
The authors found that the variance in H3K27ac signal
scales proportionally with human–chimp sequence diver-
gence. We note that sequence differences are quite low
overall (three to six substitutions per 500 bp) even at re-
gions with the biggest human–chimpanzee differences in
H3K27ac binding [44]. These results show that regions with
one or two sequence changes can have different enhancer
activity (measured by transgenic assays using luciferase or
lacZ), which may make identifying causal sequence changes
easier than in HARs with five to ten changes. Prescott et al.
speculate that the enhancer activity differences they detect
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f g
Fig. 2. Strategies to identify human-specific enhancers. a Methodology used to identify human-accelerated DNSase I hypersensitive sites (haDHSs) in [38].
Black bars, nucleotides that differ from the human sequence; blue bars, sites where all species differ from humans; dotted red lines, DHS and neutral
sequence. b Five haDHSs showed different activity with human versus chimpanzee sequences in SK-N-MC cells. c Differentially active haDHS12/DAR12
(asterisk) overlaps previously identified HACNS219 [23] and is located near RNF145, a ring finger gene involved in cellular cholesterol metabolism [101]. d
Brains of species studied in [43] (approximately to scale, colors label regions). Tree indicates approximate timing of splits between lineages (millions of years
ago). e Workflow and (bottom) fraction of H3K27ac peaks that is differentially enriched (DE) between species per brain region. f Left: Percentage of HARs
within conserved regulatory elements (CREs). Right: Most of the 240 HAR-containing CREs that align across species were not DE in human versus macaque
and chimpanzee. g H3K27ac tracks for mouse, macaque, chimpanzee, and human cerebellum. Gray, shared enhancers; purple, DE enhancers higher in
human versus macaque; red, HAR87. Enhancers gained in mouse or lost in primates (yellow) may compensate for the enhancer gained in primates (light
blue) upstream of the CADM1 gene. Abbreviations: CB cerebellum, PFC prefrontal cortex, PcGm precentral gyrus, OP occipital pole, WM white matter, CN
caudate nucleus, TN thalamic nucleus, Put putamen. Reproduced partially from [38, 43], with permission
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ing motifs, such as one called Coordinator. However, since
enhancer assays are not highly quantitative (see below) and
cannot identify upstream causes of differences in reporter
gene activity, further functional experiments are important
to validate the expression differences and test the hypoth-
esis that transcription factor binding changes played a
causal role in these regions.
Overall, these studies discovered many genome se-
quences with human-specific epigenomic signatures, which
are exciting catalogs of putative regulatory elements for fu-
ture studies. Since many of these regions are not deeply
conserved across mammals, they complement previously
identified HARs. However, most of the elements show little
or no evidence of human-specific sequence change, sug-
gesting that the causal mutations are in trans or that the
catalogs contain many false positives due to the many chal-
lenges of cross-species functional genomics, such as anti-
body affinity, low samples sizes, and matching cell
composition and developmental stage. As Prescott et al.
note, regions with fewer sequence changes than a typical
HAR can show enhancer activity differences [44], though
we emphasize that it is challenging to discriminate these
from the many cases where an equivalent number of se-
quence changes causes no activity difference. More func-
tional validation of predicted differences in regulatoryactivity (for example, with reporter assays or CRISPR/Cas9
screens) will help to determine the false positive rate.
Meanwhile, we should be careful when interpreting chro-
matin immunoprecipitation data since protein–DNA bind-
ing events cannot be directly translated into regulatory
function, as has been discussed elsewhere [47–49]. Another
challenge is evaluating the net effect of all genetic and epi-
genetic changes within a locus on species-specific gene ex-
pression (reviewed in [49]), which is particularly difficult
when regulatory elements function synergistically or redun-
dantly (Fig. 3 and below).
Transgenic approaches to study the functional
impact of non-coding evolution
One approach to investigating the functional effects of
human-specific non-coding sequences is to introduce
them into model organisms. Despite differences in anat-
omy and genetic networks across species [50], transgenic
and mutant mouse models have been useful for character-
izing human-specific genes, such as ARHGAP11B [51]
and SRGAP2C [52], and human-specific gene variants,
such as FOXP2 [53, 54]. Predicted enhancers can also be
validated and tested for effects of sequence differences
using transient or stable reporter assays in mouse and zeb-
rafish. In general, in transient transgenic enhancer assays
(where the F0 generation is analyzed) enhancer function
ab
c
Fig. 3. Evolutionary mechanisms at the level of gene regulatory regions.
a An example of accelerated sequence evolution affecting one enhancer
in a locus and leading to gain of an expression domain in the
developing forebrain. We characterized one such gain of function HAR in
Kamm et al. [57]. b Shadow enhancers are multiple enhancers that direct
a similar gene expression pattern and thus overlap in function. As such,
they can act cooperatively to confer robustness in different physiological
situations [77, 78]. The example shown is based on the work of Lam
et al. [78], where two enhancers direct expression to the Arcuate Nucleus
and both must be deleted in mice to produce a dramatic change in
expression and phenotype. c Enhancer turnover is when one enhancer
disappears and a new one appears in the same regulatory region,
replacing the lost function. In the example shown by Domené et al. [72],
turnover resulted in no net change in expression or phenotype
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onic stages, and not in adult tissues. Although we found
that many HARs appear to function during development
[10], a substantial fraction likely cannot be characterized
with this approach. Generation of stable transgenic lines
(where the F1 generation is analyzed) could facilitate the
analysis of many more developmental stages and adult ex-
pression. However, the low throughput of transgenic ex-
periments has limited their utility for characterizing large
catalogs of human-specific regulatory elements.
Despite these caveats, a number of human-specific non-
coding sequences have been functionally characterized as
enhancers in vivo with reporter assays in transgenic animal
models. These include two conserved elements deleted in
humans (hCONDELs) [55], nearly 70 HARs (summarizedin [10]), including nine haDHSs, and an additional seven
haDHSs that do not overlap HARs [38]. Reporter assays in
transgenic animals can also be used to test the hypothesis
that human-specific mutations in non-coding elements
altered their enhancer activity, and indeed several HARs
and haDHSs show expression differences between con-
structs carrying the chimpanzee versus human sequence
[37, 56–59] (Table 1). It is important to note that transient
transgenics can capture gains and losses of enhancer activ-
ity in specific tissues or cell types (expression patterns), but
they are not quantitative (expression level depends on
number and location of random genomic integrations) and
hence are unable to capture changes in activity levels.
These studies aiming to analyze the function of human-
specific non-coding sequences and then to study them
comparatively with transgenic model organism enhancer
assays are adding valuable information about the functional
impact of human-specific DNA changes. Looking ahead, it
will be important to supplement these with additional ap-
proaches to link enhancer activity differences to gene ex-
pression and phenotypes.
Massively parallel reporter assays (MPRAs) show
promise in cell lines and may become practical in whole
animals [60–62]. In this technique, a library of candidate
regulatory enhancer DNA sequences is cloned into a re-
porter construct containing a unique DNA barcode that
will be transcribed if the enhancer is active. RNA-
sequencing of the DNA barcodes enables quantitative
measurements of enhancer activity, including effects of
individual nucleotide variants [62]. Two potential limita-
tions of this technique are length of the candidate en-
hancers (<200 bp with current DNA synthesis methods)
and the fact that they are usually evaluated outside of
their genome context. Knock-in strategies where regula-
tory element variants are replaced in the analyzed locus
(such as via CRISPR/Cas9 genome editing) could ad-
dress this issue. Low throughput transgenic and mutant
model animals can complement both techniques. A
combination of methods can together enable tests of hy-
potheses about the effects of human-specific variants on
molecular and organismal phenotypes.
Human variation links accelerated regions to
phenotypes
Another way to associate human-specific non-coding re-
gions with traits is to investigate associations between any
polymorphisms they harbor and phenotypic variability in
humans. The polymorphic sites will be relatively recent
mutations that are largely distinct from differences be-
tween human and chimpanzee reference genomes. But
they may nonetheless shed light on the general function of
the accelerated regions in which they occur. For example,
gene copy number variants in the human-specific pericen-
tric inversion of chromosome 1 have been associated with
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63–65], and we showed that HARs that are conserved in
primates but not across all mammals are associated with
schizophrenia [66]. As many more human genomes are
sequenced, population genetic variation in and near to
HARs will also help researchers to test hypotheses about
the evolutionary forces that created and maintain HARs
(Box 1, Fig. 3).
Leveraging this approach, Doan et al. sequenced HARs
in individuals with autism spectrum disorder (ASD) and
unaffected controls [60]. ASD was associated with a sig-
nificant 43% excess of rare biallelic variants in HARs. The
authors showed that 29% of these variants alter enhancer
activity in primary mouse neurospheres using a custom
MPRA. They further identified rare homozygous muta-
tions with active regulatory marks near neurodevelopmen-
tal and disease-associated genes in ASD patients who lack
causal coding mutations. Using luciferase reporter assays
and transgenic mice, the authors show that one particular
ASD-associated HAR variant (HACNS426) that was pre-
viously shown to interact with the neuronal morphology
gene Cux1 [67–70] is an enhancer (Fig. 4). The authors re-
port that transgenic mice carrying the mutant allele fused
to the CUX1 promoter and to GFP show elevateda b
Fig. 4 Testing HARs and HAR sequence variants for enhancer activity with repo
(HACNS426) for enhancer activity in mouse embryos. The experiment compares
minor allele (A) that is never homozygous in healthy controls and is predicted t
two HACNS426 alleles fused to the human CUX1 promoter and the GFP reporte
assay enhancer activity, brain slices from embryonic day E16.5 are stained for GF
(above) versus A allele (below). The major strength of the approach is the spatia
not being highly quantitative, the use of mouse to compare human and chimp
permission from [23]. The study also performed in vitro luciferase reporter assay
promoter. b Massively parallel reporter assays (MPRAs) enable thousands of repo
associated with a unique DNA barcode (such as 20-bp sequence). RNA sequenc
each HAR variant. MPRAs are high throughput, allowing thousands of HARs and
of single nucleotide differences with moderate effects on expression. Current w
segments less than 200 bp and being restricted to testing in cell lines or mouseexpression of the reporter gene in the developing brain
compared to the wild-type allele. But it is important to re-
member that transgenic enhancer assays cannot capture
quantitative expression differences (see above).
The study of Doan et al. demonstrates the potential for
human sequencing studies coupled with deep phenotyping
to shed light on HAR function. Using associations between
specific HARs and ASD, the authors conclude that many
HARs are essential for normal development. Even though
the ASD-associated mutations are different from the substi-
tutions that happened during human evolution, they none-
theless help to annotate the function of the genomic region
containing a HAR. Polymorphic deletions of HARs could
similarly be used to annotate their functions. Doan et al.
further hypothesize that human-specific mutations in
HARs could have altered social and/or cognitive behavior.
To test this hypothesis precisely with medical re-
sequencing requires that specific human–chimp differences
and combinations thereof be polymorphic in living humans
or primates. As targeted sequencing (for example, with mo-
lecular inversion probes [71]) enables HARs to be se-
quenced in millions of individuals, it will become clear how
many human–chimp differences are present in modern
humans. One caveat is that the genomes of modernrter assays. a Example of a transient transgenic reporter assay to test a HAR
enhancer activity of the major allele (G) to that of the autism-associated
o change transcription factor binding. Top: constructs carrying each of the
r gene are separately injected into single-cell mouse embryos. Bottom: to
P. The authors observed differences in GFP expression with the G allele
l and cellular resolution of in vivo measurements, while weaknesses include
anzee variants, low throughput, and relatively high cost. Adapted with
s and showed HANCS426 interacts with the dosage-sensitive CUX1
rter constructs to be tested as a library (top) in which each HAR variant is
ing of barcodes (bottom) provides a quantitative estimate of the activity of
variants thereof to be tested, and they are quantitative, enabling detection
eaknesses of the technology include being limited to HARs or HAR
tail vein assays
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populations, so phenotype associations of HAR mutations
must be interpreted in the context of the modern genetic
background. For this approach to be a useful path to eluci-
dating HAR functions in humans, it will also be important
to couple sequencing data with a very wide range of reliably
measured phenotypes ranging from diseases to behaviors.
This is an exciting and increasingly feasible direction.
Changing things so everything stays the same?
Regulatory element turnover and compensatory
evolution
To measure the effects of non-coding mutations on ex-
pression and phenotypes, we must move towards consid-
ering the whole regulatory region of a gene, as well as
changes in trans (such as, expression and activity of up-
stream regulators). One reason for this is that regulatory
elements without sufficient sequence similarity to be
aligned across species can direct conserved expression
patterns, a phenomenon known as ‘enhancer turnover’
[72–74] (Fig. 3). Another consideration is the fact that
regulatory elements interact with each other to drive
gene expression, which means that non-coding muta-
tions can amplify or buffer one another even if they are
not adjacent. One particular type of compensation
across regulatory elements involves ‘shadow enhancers’,
which are distinct sequences capable of guiding similar
spatiotemporal expression patterns [75–80] (Fig. 3). This
apparently redundant function may ensure robust, pre-
cise, and stable regulation [77, 78]. Thus, gene expres-
sion evolution cannot be easily predicted from a single
human-specific regulatory element without evaluating
the complete regulatory landscape of the locus.
Most human-specific regulatory elements have none-
theless been characterized one at a time, or even one
mutation at a time. Supporting the idea that this limits
our ability to predict expression divergence, Vermunt
et al. showed that many loci contain both gains and
losses of predicted enhancers (4.9–10.3% across brain re-
gions of mice, macaques, chimpanzees, and humans)
[43]. For example, the locus containing HAR87 harbors
multiple other predicted enhancers with increased or de-
creased activity during human evolution, measured via
chromatin capture coverage (Fig. 2). These other
changes could compensate for or otherwise interact with
changes in the activity of HAR87. To investigate this
possibility, comparative genomics should be combined
with functional genomics assays, especially those that do
not depend on antibody affinities (for example, chroma-
tin capture, open chromatin).
An emerging approach is to leverage high-throughput
genetic screens that can probe combinations of mutations
across a locus, for example, via CRISPR genome editing
[81, 82]. Using a combination of CRISPR activation andinhibition, as well as knock-outs and knock-ins, it will be
possible to study the effect of human–chimpanzee non-
coding sequence differences on gene expression in cells or
in models such as mice. These studies should investigate all
the putative regulatory regions of a gene individually and in
combination to truly decipher the net regulatory effects.Thinking again: what are we missing in the study
of genetic bases of human evolution?
The past decade has seen significant progress towards ad-
dressing the major hurdles of associating human-specific
non-coding elements with traits that make our species
unique. Functional genomics has been transformative in
terms of annotating and prioritizing HARs, and it has also
been used directly to identify novel human-specific regula-
tory elements that are not divergent enough in sequence to
be detectable in genome-wide tests for accelerated se-
quence evolution. As the mechanisms of gene regulation
are increasingly understood, the functional effects of
human-specific non-coding mutations are becoming less
mysterious. High-throughput functional assays, such as
massively parallel reporter assays and CRISPR screens, are
increasing the numbers of characterized human-specific
regulatory elements by orders of magnitude. Meanwhile,
targeted and whole genome sequencing of thousands of
people is enabling rare variant association and linkage stud-
ies that connect non-coding elements to traits and may
even reveal the phenotypes of individuals carrying specific
ancestral versus derived haplotypes. Human evolutionary
studies will always be challenged by our inability to test spe-
cific hypotheses about genetic changes in the correct organ-
ismal context (an ancestral human). However, we now have
a much broader collection of complementary research tools
to address this problem, including on one hand genome
editing of stem cell-derived cell lines, organoids, human
primary cells, and model organisms, and on the other hand
deep phenotyping and sequencing of humans and other
primates to capture natural variation.
Despite these exciting advances towards understanding
the role of regulatory changes in human evolution, it is im-
portant to ask what hurdles still remain. One major barrier
is our very limited ability to assay functions of regulatory el-
ements other than enhancers. Genome editing is helping to
address this bias by enabling researchers to introduce indi-
vidual human mutations or to knock out single human-
specific elements [81, 82]. By performing these experiments
in primate cells, human cells, and model organisms, it will
be feasible to characterize putative human-specific insulat-
ing and repressing elements in terms of their downstream
effects on molecular and cellular phenotypes. The develop-
ment of new high-throughput assays to read out regulatory
functions other than enhancing gene expression (such as
repression or insulation) will help as well.
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evolution is the vast sequence differences encoded within
SVs, many of which are missing or incorrect in human
and non-human primate reference genomes [83]. Even
within the SVs that have been accurately compared across
primates, human non-coding evolution is relatively unex-
plored, due largely to the technical challenges of function-
ally testing regions with duplications and complex
genomic architectures. SVs have immense potential to
alter regulatory elements and their interactions with target
genes. For example, inserting or deleting topologically as-
sociating domain (TAD) boundaries, which are often con-
served across cell types and species [84], can associate
regulatory elements with new genes (termed ‘enhancer
hijacking’) or insulate them from their ancestral gene
targets [85, 86]. It will be exciting to explore the evolution
of human gene expression in terms of 3D genome
organization and its effects on regulatory interactions.
Outlook: what will it take to crack the code?
The next decade could be the one in which the regula-
tory code is cracked, opening the door to reading out
the functional effects of non-coding changes that distin-
guish humans from other primates. To realize this goal,
we should not only push to characterize the human–
chimp differences for which we already have functional
hypotheses. We must also continue to ask ‘what gen-
omic regions are missing from our analyses?’ and ‘where
do current models of gene regulation fail to explain di-
vergently expressed genes?’
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